Brenner Alina V, Linet Martha S, Fine Howard A, Shapiro William R, Selker Robert G, Black Peter M, Inskip Peter D
Radiation Epidemiology Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892-7362, USA.
Int J Cancer. 2002 May 10;99(2):252-9. doi: 10.1002/ijc.10320.
To explore a possible influence of the immune system in the development of brain tumors, we evaluated the relationship between history of allergies and autoimmune diseases and risk of brain tumors within a large, hospital-based case-control study. Cases (n = 782) were patients recently diagnosed with glioma (n = 489), meningioma (n = 197) or acoustic neuroma (n = 96) at hospitals in Boston, Phoenix and Pittsburgh (USA). Controls (n =799) were patients hospitalized for a variety of nonmalignant conditions and frequency-matched to cases by hospital, age, sex, race/ethnicity and distance of residence from hospital. Research nurses collected data by personal interview of patients. Odds ratios (OR) and 95% confidence intervals (CI) were calculated using unconditional logistic regression. There was a significant inverse association between glioma and history of any allergies (OR = 0.67, 95% CI = 0.52-0.86) or autoimmune diseases (OR = 0.49, 95% CI = 0.35-0.69). No significant associations were evident for meningioma or acoustic neuroma with history of any allergies. An inverse association was observed between meningioma and history of autoimmune diseases (OR = 0.59, 95% CI = 0.38-0.92). There was a suggestion of interaction between allergies and autoimmune diseases on risk of glioma (p = 0.06), with subjects having both conditions being at lowest risk (OR = 0.24, 95% CI = 0.14-0.42). Among the specific conditions, asthma and diabetes showed the most consistent associations (OR = 0.63, 95% CI = 0.43-0.92 and OR = 0.44, 95% CI = 0.27-0.70, respectively). Our results add to evidence that persons with allergies or autoimmune diseases are at reduced risk of glioma. The basis of the associations is not clear, but they might imply a role of immunologic factors in the development of brain tumors. Published 2002 Wiley-Liss, Inc.
为了探究免疫系统在脑肿瘤发生发展过程中可能存在的影响，我们在一项基于医院的大型病例对照研究中，评估了过敏史和自身免疫性疾病与脑肿瘤风险之间的关系。病例组（n = 782）为近期在美国波士顿、凤凰城和匹兹堡的医院被诊断为神经胶质瘤（n = 489）、脑膜瘤（n = 197）或听神经瘤（n = 96）的患者。对照组（n = 799）为因各种非恶性疾病住院的患者，根据医院、年龄、性别、种族/民族以及居住地与医院的距离与病例组进行频率匹配。研究护士通过对患者进行个人访谈来收集数据。使用无条件逻辑回归计算比值比（OR）和95%置信区间（CI）。神经胶质瘤与任何过敏史（OR = 0.67，95% CI = 0.52 - 0.86）或自身免疫性疾病史（OR = 0.49，95% CI = 0.35 - 0.69）之间存在显著的负相关。脑膜瘤或听神经瘤与任何过敏史之间未发现明显关联。脑膜瘤与自身免疫性疾病史之间存在负相关（OR = 0.59，95% CI = 0.38 - 0.92）。过敏和自身免疫性疾病在神经胶质瘤风险上存在相互作用的迹象（p = 0.06），同时患有这两种疾病的受试者风险最低（OR = 0.24，95% CI = 0.14 - 0.42）。在特定疾病中，哮喘和糖尿病表现出最一致的关联（分别为OR = 0.63，95% CI = 0.43 - 0.92和OR = 0.44，95% CI = 0.27 - 0.70）。我们的结果进一步证明，患有过敏或自身免疫性疾病的人患神经胶质瘤的风险降低。这些关联的基础尚不清楚，但可能意味着免疫因素在脑肿瘤发生发展中起作用。2002年由威利 - 利斯公司出版。
